<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nefr</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology (Saint-Petersburg)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-6274</issn><issn pub-type="epub">2541-9439</issn><publisher><publisher-name>Pavlov First Saint-Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.36485/1561-6274-2021-25-4-57-63</article-id><article-id custom-type="elpub" pub-id-type="custom">nefr-2010</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ. КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES. CLINICAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Молекулярные механизмы развития осложнений нефролитиаза, ассоциированного с сахарным диабетом 2-го типа</article-title><trans-title-group xml:lang="en"><trans-title>Molecular mechanisms of complications development of nephrolithiasis associated with  diabetes type 2</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8070-2242</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Баринов</surname><given-names>Э. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Barinov</surname><given-names>E. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Проф. Баринов Эдуард Федорович, д-р мед. наук, кафедра гистологии, цитологии и эмбриологии. </p><p>83003, Украина, г. Донецк, пр. Ильича, д. 16</p><p>Тел.: (+38) 050 069 0470</p></bio><bio xml:lang="en"><p>Prof. Еduard F. Barinov MD, PhD, DMedSci</p><p>83003, Donetsk, Ukraine, M.Gorky Donetsk National Medical University</p><p>Phone: (+38)0500690470</p></bio><email xlink:type="simple">barinov.ef@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8785-1662</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Григорян</surname><given-names>Х. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Grigoryan</surname><given-names>Kh. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Григорян Хачен Владимирович, канд. мед. наук , кафедра урологии</p><p>83003, Украина, г. Донецк, пр. Ильича, д. 16</p><p>Тел.: (+38 ) 050 208 0622</p></bio><bio xml:lang="en"><p>Khachen V. Grigoryan, MD, PhD</p><p>83003, Donetsk, Ukraine, M. Gorky Donetsk National Medical University</p><p>Phone: (+38 ) 050 208 0622</p></bio><email xlink:type="simple">khachengrigoryan@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7809-5260</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Малинин</surname><given-names>Ю. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Malinin</surname><given-names>Y. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Малинин Юрий Юртевич, канд. мед. наук, кафедра урологии</p><p>83003, Украина, г. Донецк, пр. Ильича, д. 16</p><p>Тел.: (+38 ) 050 764 4183</p></bio><bio xml:lang="en"><p>Yuri Yu. Malinin MD, PhD</p><p>83003, Donetsk, Ukraine, M. Gorky Donetsk National Medical University</p><p>Phone: (+38 ) 050 764 4183</p></bio><email xlink:type="simple">jora2@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Донецкий национальный медицинский университет им. М. Горького</institution><country>Украина</country></aff><aff xml:lang="en"><institution>M. Gorky Donetsk National Medical University</institution><country>Ukraine</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>15</day><month>07</month><year>2021</year></pub-date><volume>25</volume><issue>4</issue><fpage>57</fpage><lpage>63</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Баринов Э.Ф., Григорян Х.В., Малинин Ю.Ю., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Баринов Э.Ф., Григорян Х.В., Малинин Ю.Ю.</copyright-holder><copyright-holder xml:lang="en">Barinov E.F., Grigoryan K.V., Malinin Y.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephrolog.ru/jour/article/view/2010">https://journal.nephrolog.ru/jour/article/view/2010</self-uri><abstract><sec><title>ВВЕДЕНИЕ</title><p>ВВЕДЕНИЕ. До настоящего времени отсутствует понимание особенностей клинического течения и причин прогрессирования развития осложнений нефролитиаза (НЛТ), ассоциированного с сахарным диабетом (СД), что ограничивает разработку эффективных методов лечения пациентов с данной патологией почек.</p><p>ЦЕЛЬ ИССЛЕДОВАНИЯ – изучить молекулярные механизмы развития гематурии и лейкоцитурии при коморбидности нефролитиаза с СД 2-го типа.</p></sec><sec><title>ПАЦИЕНТЫ И МЕТОДЫ</title><p>ПАЦИЕНТЫ И МЕТОДЫ. В работе проанализированы клинико-инструментальные и лабораторные данные 196 пациентов с НЛТ; в исследование включены 48 (24,5 %) пациентов, у которых имела место коморбидность НЛТ с СД 2-го типа. Всем пациентам на этапе госпитализации проведено комплексное клиническое и лабораторное обследование по традиционной схеме, принятой для диагностики НЛТ. Для анализа функциональной активности рецепторов тромбоцитов (Тц) использовали агонисты: АТФ, ФАТ и коллаген (Sigma) в концентрациях ЕС50, вызывающих агрегацию на уровне 50 % у здоровых лиц. Оценку агрегации Тц проводили турбидиметрическим методом на анализаторе ChronoLog (USA).</p></sec><sec><title>РЕЗУЛЬТАТЫ</title><p>РЕЗУЛЬТАТЫ. Из 48 пациентов, у которых НЛТ ассоциирована с СД 2-го типа, микрогематурия имела место у 27 (56,2 %) пациентов, у 21 (43,8 %) – макрогематурия. При микроскопии мочи у пациентов с коморбидностью НЛТ выявлено большее количество эритроцитов (р=0,014); в данной когорте больных чаще встречалась макрогематурия (р=0,034) и лейкоцитурия (р=0,003). Развитие осложнений нефролитиаза происходило на фоне повышения реактивности P2Х-рецепторов, ФАТ-рецептора и GPVI-рецептора (р&lt;0,001) Тц по сравнению с таковой у больных с НЛТ без СД. Прогрессирование лейкоцитурии сопровождалось увеличением выраженности гематурии и проявлялось возрастанием активности GPVI- рецепторов (р&lt;0,001).</p></sec><sec><title>ЗАКЛЮЧЕНИЕ</title><p>ЗАКЛЮЧЕНИЕ. Влияние СД на патогенез осложнений НЛТ связано с усилением ишемии тканей почки, системной воспалительной реакции и ремоделирования стенки сосудов. Активность Р2Х-, ФАТ- и GPVI- рецепторов тромбоцитов можно рассматривать как систему потенциальных биомаркеров и прогностических факторов развития осложнений при коморбидности НЛТ с СД 2 типа.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>BACKGROUND</title><p>BACKGROUND. Until recently there is no understanding of the clinical features and the reasons for the progression of complications of diabetes-associated nephrolithiasis (NLT) which limits the development of effective treatment for patients with this kidney pathology.</p><p>THE AIM was to investigate the molecular mechanisms of hematuria and leukocyturia in the comorbidity of nephrolithiasis with type 2 diabetes. </p></sec><sec><title>PATIENTS AND METHODS</title><p>PATIENTS AND METHODS. The study analyzed the clinical, instrumental, and laboratory data of 196 patients with NLT; the study included 48 (24.5 %) patients with comorbidity of NLT with type 2 diabetes. All patients at the stage of hospitalization underwent a comprehensive clinical and laboratory examination according to the traditional scheme adopted for the diagnosis of NLT. ATP, PAF, and collagen (Sigma) agonists at EC50 concentrations causing aggregation at the 50 % level in healthy individuals were used to analyze the functional activity of platelet (PLT) receptors. PLT aggregation was assessed by the turbidimetric method using a ChronoLog analyzer (USA). </p></sec><sec><title>RESULTS</title><p>RESULTS. Microhematuria occurred in 27 (56.2 %) patients and gross hematuria in 21 (43.8 %) patients out of 48 patients with type 2 diabetes-associated NLT. Microscopy of urine in patients with comorbidity of NLT revealed a greater number of erythrocytes (P = 0.014); gross hematuria (P = 0.034) and leukocyturia (р=0,003) were more common in this cohort of patients. NLT complications occurred against the background of increased reactivity of P2X receptors, PAF receptor, and GPVI receptor (p &lt;0.001) of PLT compared with that in patients with NLT without DM. The progression of leukocyturia was accompanied by increased severity of hematuria and was manifested by increased activity of GPVI receptors (p &lt;0.001). </p></sec><sec><title>CONCLUSION</title><p>CONCLUSION. The influence of diabetes on the pathogenesis of NLT complications is associated with increased ischemia of kidney tissue, systemic inflammatory response, and vascular wall remodeling. The activity of P2X, PAF, and GPVI platelet receptors could be considered as a system of potential biomarkers and prognostic factors of complications in the comorbidity of NLT with type 2 diabetes.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>нефролитиаз</kwd><kwd>СД 2 типа</kwd><kwd>гематурия</kwd><kwd>лейкоцитурия</kwd><kwd>рецепторы тромбоцитов</kwd></kwd-group><kwd-group xml:lang="en"><kwd>nephrolithiasis</kwd><kwd>type 2 diabetes</kwd><kwd>hematuria</kwd><kwd>leukocyturia</kwd><kwd>platelet receptors</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kim S, Chang Y, Jung H. et al. Glycemic Status, Insulin Resistance, and the Risk of Nephrolithiasis: A Cohort Study. Аm J Kidney Dis 2020 ;76(5):658–668.e1. doi: 10.1053/j.ajkd.2020.03.013</mixed-citation><mixed-citation xml:lang="en">Kim S, Chang Y, Jung H. et al. Glycemic Status, Insulin Resistance, and the Risk of Nephrolithiasis: A Cohort Study. Аm J Kidney Dis 2020 ;76(5):658–668.e1. doi: 10.1053/j.ajkd.2020.03.013</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Prezioso D, Strazzullo P, Lotti T. et al. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group. Arch Ital Urol Androl 2015;87(2):105–120. doi: 10.4081/aiua.2015.2.105</mixed-citation><mixed-citation xml:lang="en">Prezioso D, Strazzullo P, Lotti T. et al. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group. Arch Ital Urol Androl 2015;87(2):105–120. doi: 10.4081/aiua.2015.2.105</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Olcucu MT, Teke K, Yalcin S. Characterizing the Association Between Toll-like Receptor Subtypes and Nephrolithiasis With Renal Inflammation in an Animal Model. Urology 2018;111:238. e1-238.e5. doi: 10.1016/j.urology.2017.09.026</mixed-citation><mixed-citation xml:lang="en">Olcucu MT, Teke K, Yalcin S. Characterizing the Association Between Toll-like Receptor Subtypes and Nephrolithiasis With Renal Inflammation in an Animal Model. Urology 2018;111:238. e1-238.e5. doi: 10.1016/j.urology.2017.09.026</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Mefford JM, Tungate RM, Amini L et al. Comparison of Urolithiasis in the Presence and Absence of Microscopic Hematuria in the Emergency Department. West J Emerg Med 2017;18(4):775– 779. doi: 10.5811/westjem.2017.4.33018</mixed-citation><mixed-citation xml:lang="en">Mefford JM, Tungate RM, Amini L et al. Comparison of Urolithiasis in the Presence and Absence of Microscopic Hematuria in the Emergency Department. West J Emerg Med 2017;18(4):775– 779. doi: 10.5811/westjem.2017.4.33018</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Lumlertgul N, Siribamrungwong M, Jaber B et al. Secondary Oxalate Nephropathy: A Systematic Review. Kidney Int Rep 2018;3(6):1363–1372. doi: 10.1016/j.ekir.2018.07.020</mixed-citation><mixed-citation xml:lang="en">Lumlertgul N, Siribamrungwong M, Jaber B et al. Secondary Oxalate Nephropathy: A Systematic Review. Kidney Int Rep 2018;3(6):1363–1372. doi: 10.1016/j.ekir.2018.07.020</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Lin B-B, Huang R-H, Lin B-L et al. Associations between nephrolithiasis and diabetes mellitus, hypertension and gallstones: A meta-analysis of cohort studies. Nephrology (Carlton) 2020;25(9):691–699. doi: 10.1111/nep.13740</mixed-citation><mixed-citation xml:lang="en">Lin B-B, Huang R-H, Lin B-L et al. Associations between nephrolithiasis and diabetes mellitus, hypertension and gallstones: A meta-analysis of cohort studies. Nephrology (Carlton) 2020;25(9):691–699. doi: 10.1111/nep.13740</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Akash MSH, Rehman K, Fiayyaz F et al. Diabetes-associated infections: development of antimicrobial resistance and possible treatment strategies. Arch Microbiol 2020;202(5):953–965. doi: 10.1007/s00203-020-01818-x</mixed-citation><mixed-citation xml:lang="en">Akash MSH, Rehman K, Fiayyaz F et al. Diabetes-associated infections: development of antimicrobial resistance and possible treatment strategies. Arch Microbiol 2020;202(5):953–965. doi: 10.1007/s00203-020-01818-x</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kim S, Chang Y, Jung H-S et al. Glycemic Status, Insulin Resistance, and the Risk of Nephrolithiasis: A Cohort Study. Am J Kidney Dis 2020;76(5):658–668.e1. doi: 10.1053/j.ajkd.2020.03.013</mixed-citation><mixed-citation xml:lang="en">Kim S, Chang Y, Jung H-S et al. Glycemic Status, Insulin Resistance, and the Risk of Nephrolithiasis: A Cohort Study. Am J Kidney Dis 2020;76(5):658–668.e1. doi: 10.1053/j.ajkd.2020.03.013</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Carbone A, Salhi YA, Tasca A et al. Obesity and kidney stone disease: a systematic review. Minerva Urol Nefrol 2018;70(4):393– 400. doi: 10.23736/S0393-2249.18.03113-2</mixed-citation><mixed-citation xml:lang="en">Carbone A, Salhi YA, Tasca A et al. Obesity and kidney stone disease: a systematic review. Minerva Urol Nefrol 2018;70(4):393– 400. doi: 10.23736/S0393-2249.18.03113-2</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wang H-F, Yu Q-Q, Zheng R-F et al. Inhibition of vascular adventitial remodeling by netrin-1 in diabetic rats. J Endocrinol 2020;244(3):445–458. doi: 10.1530/JOE-19-0258</mixed-citation><mixed-citation xml:lang="en">Wang H-F, Yu Q-Q, Zheng R-F et al. Inhibition of vascular adventitial remodeling by netrin-1 in diabetic rats. J Endocrinol 2020;244(3):445–458. doi: 10.1530/JOE-19-0258</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Binet F, Cagnone G, Crespo-Garcia S et al. Neutrophil extracellular traps target senescent vasculature for tissue remodeling in retinopathy. Science 2020;369(6506):eaay5356. doi: 10.1126/science.aay5356</mixed-citation><mixed-citation xml:lang="en">Binet F, Cagnone G, Crespo-Garcia S et al. Neutrophil extracellular traps target senescent vasculature for tissue remodeling in retinopathy. Science 2020;369(6506):eaay5356. doi: 10.1126/science.aay5356</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Correa-Costa M, Andrade-Oliveira V, Braga TT et al. Activation of platelet-activating factor receptor exacerbates renal inflammation and promotes fibrosis. Lab Invest 2014;94(4):455–466. doi: 10.1038/labinvest.2013.155</mixed-citation><mixed-citation xml:lang="en">Correa-Costa M, Andrade-Oliveira V, Braga TT et al. Activation of platelet-activating factor receptor exacerbates renal inflammation and promotes fibrosis. Lab Invest 2014;94(4):455–466. doi: 10.1038/labinvest.2013.155</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Dwyer KM, Kishore BK, Robson S. Conversion of extracellular ATP into adenosine: a master switch in renal health and disease. Nat Rev Nephrol 2020;16(9):509–524. doi: 10.1038/s41581-020-0304-7</mixed-citation><mixed-citation xml:lang="en">Dwyer KM, Kishore BK, Robson S. Conversion of extracellular ATP into adenosine: a master switch in renal health and disease. Nat Rev Nephrol 2020;16(9):509–524. doi: 10.1038/s41581-020-0304-7</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Harrison P, Mackie I, Mumford A. British Guidelines for the laboratory investigation of heritable disorders of platelet function. Brit Journal of Haematology 2011;155(1):30–44</mixed-citation><mixed-citation xml:lang="en">Harrison P, Mackie I, Mumford A. British Guidelines for the laboratory investigation of heritable disorders of platelet function. Brit Journal of Haematology 2011;155(1):30–44</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Buch A, Kaur S, Nair R et al. Platelet Volume Indices as Predictive Biomarkers for Diabetic Complications in Type 2 Diabetic Patients. J Lab Physicians 2017;9(2):84–88. doi: 10.4103/0974-2727.199625</mixed-citation><mixed-citation xml:lang="en">Buch A, Kaur S, Nair R et al. Platelet Volume Indices as Predictive Biomarkers for Diabetic Complications in Type 2 Diabetic Patients. J Lab Physicians 2017;9(2):84–88. doi: 10.4103/0974-2727.199625</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Arthur JF, Jandeleit-Dahm K, Andrews RK. Platelet Hyperreactivity in Diabetes: Focus on GPVI Signaling-Are Useful Drugs Already Available? Diabetes 2017;66(1):7–13. doi: 10.2337/db16-1098</mixed-citation><mixed-citation xml:lang="en">Arthur JF, Jandeleit-Dahm K, Andrews RK. Platelet Hyperreactivity in Diabetes: Focus on GPVI Signaling-Are Useful Drugs Already Available? Diabetes 2017;66(1):7–13. doi: 10.2337/db16-1098</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Tokarz A, Szuścik I, Kuśnierz-Cabala B et al. Extracellular Vesicles Participate in the Transport of Cytokines and Angiogenic Factors in Diabetic Patients With Ocular Complications. Folia Med Cracov 2015;55(4):35–48</mixed-citation><mixed-citation xml:lang="en">Tokarz A, Szuścik I, Kuśnierz-Cabala B et al. Extracellular Vesicles Participate in the Transport of Cytokines and Angiogenic Factors in Diabetic Patients With Ocular Complications. Folia Med Cracov 2015;55(4):35–48</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Shilpi K, Potekar RM. A Study of Platelet Indices in Type 2 Diabetes Mellitus Patients. Indian J Hematol Blood Transfus 2018;34(1):115–120. doi: 10.1007/s12288-017-0825-9</mixed-citation><mixed-citation xml:lang="en">Shilpi K, Potekar RM. A Study of Platelet Indices in Type 2 Diabetes Mellitus Patients. Indian J Hematol Blood Transfus 2018;34(1):115–120. doi: 10.1007/s12288-017-0825-9</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Pereira ADS, de Oliveira LS, Lopes TF et al. Effect of gallic acid on purinergic signaling in lymphocytes, platelets, and serum of diabetic rats. Biomed Pharmacother 2018;101:30–36. doi: 10.1016/j.biopha.2018.02.029</mixed-citation><mixed-citation xml:lang="en">Pereira ADS, de Oliveira LS, Lopes TF et al. Effect of gallic acid on purinergic signaling in lymphocytes, platelets, and serum of diabetic rats. Biomed Pharmacother 2018;101:30–36. doi: 10.1016/j.biopha.2018.02.029</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Hu L, Chang L, Zhang Y et al. Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus. Circulation 2017;136(9):817–833. doi: 10.1161/CIRCULATIONAHA.116.026995</mixed-citation><mixed-citation xml:lang="en">Hu L, Chang L, Zhang Y et al. Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus. Circulation 2017;136(9):817–833. doi: 10.1161/CIRCULATIONAHA.116.026995</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Schiattarella GG, Carrizzo A, Ilardi F et. al. Rac1 Modulates Endothelial Function and Platelet Aggregation in Diabetes Mellitus. J Am Heart Assoc 2018;7(8);pii:e007322. doi: 10.1161/JAHA.117.007322</mixed-citation><mixed-citation xml:lang="en">Schiattarella GG, Carrizzo A, Ilardi F et. al. Rac1 Modulates Endothelial Function and Platelet Aggregation in Diabetes Mellitus. J Am Heart Assoc 2018;7(8);pii:e007322. doi: 10.1161/JAHA.117.007322</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Wang B, Yee Aw T, Stokes KY. N-acetylcysteine attenuates systemic platelet activation and cerebral vessel thrombosis indiabetes. Redox Biol 2018;14:218–228. doi: 10.1016/j.redox.2017.09.005</mixed-citation><mixed-citation xml:lang="en">Wang B, Yee Aw T, Stokes KY. N-acetylcysteine attenuates systemic platelet activation and cerebral vessel thrombosis indiabetes. Redox Biol 2018;14:218–228. doi: 10.1016/j.redox.2017.09.005</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Gong D-J, Wang L, Yan Y-Y et al. Diabetes aggravates renal ischemia and reperfusion injury in rats by exacerbating oxidative stress, inflammation, and apoptosis. Ren Fail 2019;41(1):750–761. doi: 10.1080/0886022X.2019.1643737</mixed-citation><mixed-citation xml:lang="en">Gong D-J, Wang L, Yan Y-Y et al. Diabetes aggravates renal ischemia and reperfusion injury in rats by exacerbating oxidative stress, inflammation, and apoptosis. Ren Fail 2019;41(1):750–761. doi: 10.1080/0886022X.2019.1643737</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Burnstock G. Purinergic Signaling in the Cardiovascular System. Circ Res 2017;120(1):207–228. doi: 10.1161/CIRCRESAHA.116.309726</mixed-citation><mixed-citation xml:lang="en">Burnstock G. Purinergic Signaling in the Cardiovascular System. Circ Res 2017;120(1):207–228. doi: 10.1161/CIRCRESAHA.116.309726</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Wang W, Hu D, Feng Y et al. Paxillin mediates ATP-induced activation of P2X7 receptor and NLRP3 inflammasome. BMC Biol 2020;18(1):182. doi: 10.1186/s12915-020-00918-w</mixed-citation><mixed-citation xml:lang="en">Wang W, Hu D, Feng Y et al. Paxillin mediates ATP-induced activation of P2X7 receptor and NLRP3 inflammasome. BMC Biol 2020;18(1):182. doi: 10.1186/s12915-020-00918-w</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Baudel MM-A, Espinosa-Tanguma R, Nieves-Cintron M et al. Purinergic Signaling During Hyperglycemia in Vascular Smooth Muscle Cells. Front Endocrinol (Lausanne) 2020;11:329. doi: 10.3389/fendo.2020.00329</mixed-citation><mixed-citation xml:lang="en">Baudel MM-A, Espinosa-Tanguma R, Nieves-Cintron M et al. Purinergic Signaling During Hyperglycemia in Vascular Smooth Muscle Cells. Front Endocrinol (Lausanne) 2020;11:329. doi: 10.3389/fendo.2020.00329</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Quiroga J, Alarcón P, Manosalva C et.al. Mitochondria-derived ATP participates in the formation of neutrophil extracellular traps induced by platelet-activating factor through purinergic signaling in cows. Dev Comp Immunol 2020;113:103768. doi: 10.1016/j.dci.2020.103768</mixed-citation><mixed-citation xml:lang="en">Quiroga J, Alarcón P, Manosalva C et.al. Mitochondria-derived ATP participates in the formation of neutrophil extracellular traps induced by platelet-activating factor through purinergic signaling in cows. Dev Comp Immunol 2020;113:103768. doi: 10.1016/j.dci.2020.103768</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Finsterbusch M, Schrottmaier WC, Kral-Pointner J et al. Measuring and interpreting platelet-leukocyte aggregates. Platelets 2018;29(7):677–685. doi: 10.1080/09537104.2018.1430358</mixed-citation><mixed-citation xml:lang="en">Finsterbusch M, Schrottmaier WC, Kral-Pointner J et al. Measuring and interpreting platelet-leukocyte aggregates. Platelets 2018;29(7):677–685. doi: 10.1080/09537104.2018.1430358</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Lordan R, Tsoupras A, Zabetakis I et al. Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives Molecules 2019;24(23):4414. doi: 10.3390/molecules24234414</mixed-citation><mixed-citation xml:lang="en">Lordan R, Tsoupras A, Zabetakis I et al. Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives Molecules 2019;24(23):4414. doi: 10.3390/molecules24234414</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Darestani SG, Kurano M, Shinnakasu A et al. Association between changes in the mRNA expression of platelet-activating factor receptor in peripheral blood mononuclear cells and progression of diabetic nephropathy. Diabetol Int 2019;11(1):11–18. doi: 10.1007/s13340-019-00394-w31.</mixed-citation><mixed-citation xml:lang="en">Darestani SG, Kurano M, Shinnakasu A et al. Association between changes in the mRNA expression of platelet-activating factor receptor in peripheral blood mononuclear cells and progression of diabetic nephropathy. Diabetol Int 2019;11(1):11–18. doi: 10.1007/s13340-019-00394-w31.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Kurano M, Darestani SG, Shinnakasu A et al. mRNA expression of platelet activating factor receptor (PAFR) in peripheral blood mononuclear cells is associated with albuminuria and vascular dysfunction in patients with type 2 diabetes. Diabetes Res Clin Pract 2018;136:124–133. doi: 10.1016/j.diabres.2017.11.028</mixed-citation><mixed-citation xml:lang="en">Kurano M, Darestani SG, Shinnakasu A et al. mRNA expression of platelet activating factor receptor (PAFR) in peripheral blood mononuclear cells is associated with albuminuria and vascular dysfunction in patients with type 2 diabetes. Diabetes Res Clin Pract 2018;136:124–133. doi: 10.1016/j.diabres.2017.11.028</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou S-X, Huo D-M, He X-Y et al. High glucose/lysophosphatidylcholine levels stimulate extracellular matrix deposition in diabetic nephropathy via platelet-activating factor receptor. Mol Med Rep 2018;17(2):2366–2372. doi: 10.3892/mmr.2017.8102</mixed-citation><mixed-citation xml:lang="en">Zhou S-X, Huo D-M, He X-Y et al. High glucose/lysophosphatidylcholine levels stimulate extracellular matrix deposition in diabetic nephropathy via platelet-activating factor receptor. Mol Med Rep 2018;17(2):2366–2372. doi: 10.3892/mmr.2017.8102</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Pennings GJ, Yong AS, Wong C et al. Circulating levels of soluble EMMPRIN (CD147) correlate with levels of soluble glycoprotein VI in human plasma. Platelets 2014;25(8):639–642. doi: 10.3109/09537104.2013.852660</mixed-citation><mixed-citation xml:lang="en">Pennings GJ, Yong AS, Wong C et al. Circulating levels of soluble EMMPRIN (CD147) correlate with levels of soluble glycoprotein VI in human plasma. Platelets 2014;25(8):639–642. doi: 10.3109/09537104.2013.852660</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Tsuda K. Angiotensin 1-7 and the Sympathetic Nervous System in Hypertensive Kidney Disease. Am J Hypertens 2019;32(10):e3. doi: 10.1093/ajh/hpz114</mixed-citation><mixed-citation xml:lang="en">Tsuda K. Angiotensin 1-7 and the Sympathetic Nervous System in Hypertensive Kidney Disease. Am J Hypertens 2019;32(10):e3. doi: 10.1093/ajh/hpz114</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Motegi S-I, Sekiguchi A, Fujiwara Ch et al. Possible association of elevated serum collagen type IV level with skin sclerosis in systemic sclerosis. J Dermatol 2017;44(2):167–172. doi: 10.1111/1346-8138.13564</mixed-citation><mixed-citation xml:lang="en">Motegi S-I, Sekiguchi A, Fujiwara Ch et al. Possible association of elevated serum collagen type IV level with skin sclerosis in systemic sclerosis. J Dermatol 2017;44(2):167–172. doi: 10.1111/1346-8138.13564</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Xie Y, Wang Y, Ding H et al. Highly glycosylated CD147 promotes hemorrhagic transformation after rt-PA treatment in diabetes: a novel therapeutic target. J Neuroinflammation 2019;16(1):72. doi: 10.1186/s12974-019-1460-1</mixed-citation><mixed-citation xml:lang="en">Xie Y, Wang Y, Ding H et al. Highly glycosylated CD147 promotes hemorrhagic transformation after rt-PA treatment in diabetes: a novel therapeutic target. J Neuroinflammation 2019;16(1):72. doi: 10.1186/s12974-019-1460-1</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Kostov K, Blazhev A. Use of Glycated Hemoglobin (A1c) as a Biomarker for Vascular Risk in Type 2 Diabetes: Its Relationship with Matrix Metalloproteinases-2, -9 and the Metabolism of Collagen IV and Elastin. Medicina (Kaunas) 2020;56(5):E231. doi: 10.3390/medicina56050231</mixed-citation><mixed-citation xml:lang="en">Kostov K, Blazhev A. Use of Glycated Hemoglobin (A1c) as a Biomarker for Vascular Risk in Type 2 Diabetes: Its Relationship with Matrix Metalloproteinases-2, -9 and the Metabolism of Collagen IV and Elastin. Medicina (Kaunas) 2020;56(5):E231. doi: 10.3390/medicina56050231</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
